Method for producing cell-fushion type morbillivirus mutants

Details Method for producing cell-fushion type morbillivirus mutants Method for producing cell-fushion type morbillivirus mutants

2005-04-05

2005-04-05

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S212100, C424S213100, C435S235100, C435S236000, C435S320100, C435S471000, C435S091100, C536S023720

Reexamination Certificate

active

06875436

ABSTRACT:
It was found that a mutation of an amino acid at a specific position in the F protein of amorbillivirusinduces a reduction in the cell-fusion ability. By introducing this mutation, a virus having a reduced cell-fusion ability can be produced. Thus, attenuated viruses useful in the preparation of vaccines can be easily produced.

REFERENCES:
patent: 5654136 (1997-08-01), Sasaki et al.
patent: 5824777 (1998-10-01), Sasaki et al.
patent: 864 645 (1996-10-01), None
patent: WO 9716538 (1997-05-01), None
Makino (Reviews of Infectious Diseases 5:504-505, 1983).*
Buckland, R. et al., “A leucine zipper structure present in the measles virus fusion protein is not required for its tetramerization but is essential for fusion,”Journal of General Virology(1992) 73:1703-07.
Caballero, M. et al., “Measles virus fusion protein is palmitoylated on transmembrane-intracytoplasmic cysteine residues which participate in cell fusion,”Journal of Virology(Oct. 1998) 72(10): 8198-204.
Cathomen, T. et al., “Measle viruses with altered envelope protein cytoplasmic tails gain cell fusion competence,”Journal of Virology(Feb. 1998) 72(2):1224-34.
Evans, S.A. et al., “Nucleotide sequence comparisons of the fusion protein gene from virulent and attenuated strains of rinderpest virus,”Journal of General Virology(1994) 75:3611-17.
Heider, A. et al., “Comparative investigation of the long non-coding M-F genome region of wild-type and vaccine measles viruses,”Arch. Virol.(1997) 142: 2521-28.
Hu, A. et al., “Influence of N-linked oligosaccharide chains on the processing, cell surface expression and function of the measles virus fusion protein,”Journal of General Virology(1995) 76: 705-10.
Maisner, A. et al., “Recombinant measles virus requiring an exogenous protease for activation of infectivity,”Journal of General Virology(2000) 81:441-49.
Mori, T. et al., “Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus,”Virus Genes(1993) 7(1):67-81.
Nakayatama, T. et al., “Fusion-inducing capability of attenutated measles vaccine strain AIK-C,” (translation appended),Extract of 3rdMeeting of the Japanese Society for Vaccinology(Nov. 20, 1999) pp. 10,72.
Richardson, C.D. et al., “Oligopeptides That Specifically Inhibit Membrane Fusion by Paramyxoviruses: Studies on the Site of Action,”Virology(1983) 131:518-32.
Takeda, M. et al., “Measles virus attenuation associated with transcriptional impediment and a few amino acid changes in the polymerase and accessory proteins,”Journal of Virology(Nov. 1998) 72(11): 8690-96.

Affiliated with

Also associated with

Rating

Method for producing cell-fushion type morbillivirus mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for producing cell-fushion type morbillivirus mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing cell-fushion type morbillivirus mutants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3397045